ReviewPediatric nephrology (Berlin, Germany)2020
Steroid therapy in children with IgA nephropathy.
Review in Pediatric nephrology (Berlin, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2022Pooled it
- Retrospective analysis of glucocorticoid therapy in pediatric immunoglobulin A nephropathy: Kidney outcomes and efficacy.Pediatric nephrology (Berlin, Germany) · 2025Article
- To biopsy or not to biopsy a teenager with typical idiopathic nephrotic syndrome? Start steroids first.Pediatric nephrology (Berlin, Germany) · 2025Review
- Efficacy and safety of corticosteroid and immunosuppressive agent combination therapy for pediatric IgA nephropathy: a meta-analysis.Frontiers in pediatrics · 2025Review
- Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review.Canadian journal of kidney health and disease · 2025Review
- Combined Therapy with Azathioprine, Prednisone, and Enalapril in Children with IgAN and IgAVN.Journal of clinical medicine · 2024Article
- A lack of KDIGO guidelines for adolescents and young adults with IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2024Review
- Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial.Pediatric nephrology (Berlin, Germany) · 2023Review
- Association between glomerular C4d deposition, proteinuria, and disease severity in children with IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2023Article
- Potential of soluble (pro)renin receptor in kidney disease: can it go beyond a biomarker?American journal of physiology. Renal physiology · 2022Review
- Management of IgA Nephropathy in Pediatric Patients.Children (Basel, Switzerland) · 2022Article
- Clinicopathological significance of glomerular capillary IgA deposition in childhood IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2021Article
- New therapeutic perspectives for IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2021Review
- Remission of Proteinuria May Protect against Progression to Chronic Kidney Disease in Pediatric-Onset IgA Nephropathy.Journal of clinical medicine · 2020Article
- Crescentic IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2020Article
- Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood.Frontiers in pediatrics · 2020Review
- Nephropathy in a Child with Severe Recessive Dystrophic Epidermolysis Bullosa Treated with Cyclophosphamide: A Case Report.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is one the most common primary glomerulonephritis in children and adolescents worldwide, with 20% of children developing end-stage kidney disease (ESKD) within 20 years of diagnosis. There is a need for treatment guidelines, especially for steroids in children with primary IgAN, since the STOP-IgA trial casts doubts on the use of steroids in adults with intermediate risk. Pediatricians are prone to prescribe steroids in addition to renin-angiotensin system blockade (RASB) when proteinuria is > 0.5 g/l, eGFR deteriorates < 70 ml/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.